Aggressive B cell lymphomas retain ATR-dependent determinants of T cell exclusion from the germinal center dark zone
- Autori: Cancila, V.; Bertolazzi, G.; Chan, A.; Medico, G.; Bastianello, G.; Morello, G.; Paysan, D.; Lai, C.; Hong, L.; Shenoy, G.; Jaynes, P.; Schiavoni, G.; Mattei, F.; Piconese, S.; Revuelta, M.; Noto, F.; Businaro, L.; De Ninno, A.; Cammarata, I.; Pagni, F.; Venkatachalapathy, S.; Sangaletti, S.; Di Napoli, A.; Cicio, G.; Vacca, D.; Lonardi, S.; Lorenzi, L.; Ferreri, A.; Belmonte, B.; Liu, M.; Lakshmanan, M.; Ong, M.; Zhang, B.; See, T.; Lam, K.; Varano, G.; Colombo, M.; Bicciato, S.; Inghirami, G.; Cerchietti, L.; Ponzoni, M.; Zappasodi, R.; Metzger, E.; Beechem, J.; Facchetti, F.; Foiani, M.; Casola, S.; Jeyasekharan, A.; Tripodo, C.
- Anno di pubblicazione: 2025
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/692385
Abstract
The germinal center (GC) dark zone (DZ) and light zone represent distinct anatomical regions in lymphoid tissue where B cell proliferation, immunoglobulin diversification, and selection are coordinated. Diffuse large B cell lymphomas (DLBCLs) with DZ-like gene expression profiles exhibit poor outcomes, though the reasons are unclear and are not directly related to proliferation. Physiological DZs exhibit an exclusion of T cells, prompting exploration of whether T cell paucity contributes to DZ-like DLBCL. We used spatial transcriptomic approaches to achieve higher resolution of T cell spatial heterogeneity in the GC and to derive potential pathways that underlie T cell exclusion. We showed that T cell exclusion from the DZ was linked to DNA damage response (DDR) and chromatin compaction molecular features characterizing the spatial DZ signature, and that these programs were independent of activation-induced cytidine deaminase (AID) activity. As ATR is a key regulator of DDR, we tested its role in the T cell inhibitory DZ transcriptional imprint. ATR inhibition reversed not only the DZ transcriptional signature, but also DZ T cell exclusion in DZ-like DLBCL in vitro microfluidic models and in in vivo samples of murine lymphoid tissue. These findings highlight that ATR activity underpins a physiological scenario of immune silencing. ATR inhibition may reverse the immune-silent state and enhance T cell-based immunotherapy in aggressive lymphomas with GC DZ-like characteristics.
